Biomerica Inc (BMRA)vsNovartis AG ADR (NVS)
BMRA
Biomerica Inc
$2.18
+0.93%
HEALTHCARE · Cap: $6.61M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1307457% more annual revenue ($56.58B vs $4.33M). NVS leads profitability with a 23.9% profit margin vs -96.5%. NVS earns a higher WallStSmart Score of 51/100 (C-).
BMRA
Avoid26
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.1%
Fair Value
$6.01
Current Price
$2.18
$3.83 discount
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -94.3% — below average capital efficiency
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : BMRA
The strongest argument for BMRA centers on Debt/Equity, Price/Book.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : BMRA
The primary concerns for BMRA are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
BMRA profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.52 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 26/100), backed by strong 23.9% margins. BMRA offers better value entry with a 62.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biomerica Inc
HEALTHCARE · MEDICAL DEVICES · USA
Biomerica Inc. (Ticker: BMRA) is an innovative biotechnology company specializing in the development and manufacturing of cutting-edge diagnostic solutions across the medical and food sectors. With a strong focus on proprietary testing methods for managing metabolic diseases, gastrointestinal disorders, and food intolerances, Biomerica is committed to improving healthcare outcomes. The company actively engages in strategic research collaborations, positioning itself to address critical unmet medical needs and harness growth opportunities in the rapidly evolving diagnostics landscape. Leveraging technological advancements and a patient-centered approach, Biomerica is well-positioned to lead transformational changes in global healthcare diagnostics.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?